Abstract

Sepsis is one of the medical emergencies, and its early detection, within the first hours of development, and proper management improve outcomes. Molecular diagnostic assays using whole blood collected from patients with suspected sepsis have been developed, but the decision making is difficult because of the possibility of false positives, due to contamination. Here, we evaluated the performance of the reverse blot hybridization assay (REBA) Sepsis-ID test for the detection of sepsis-causing microorganisms using whole-blood samples. In addition, the concentrations of C-reactive protein (CRP) and procalcitonin (PCT) were determined to evaluate whether these biomarkers can provide criteria for performing REBA Sepsis-ID in clinical settings. For this study, EDTA-anticoagulated whole blood was simultaneously collected for REBA Sepsis-ID and blood culture from 440 patients with suspected sepsis, from January to October 2015. In addition, CRP and PCT concentrations were measured in 227 patients. The overall positive rates of REBA Sepsis-ID and blood culture were 16.6% (73/440) and 13.9% (61/440), respectively. The pathogen-positive rates of REBA Sepsis-ID and blood culture were 9.8% (43/440) and 9.5% (42/440), respectively. The areas under the receiver operating characteristic (AUROC) curves of PCT and CRP for predicting pathogen-positive results of REBA Sepsis-ID were 0.72 and 0.69, respectively. The PCT concentrations in the group of patients aged ≥50 years were significantly higher than those in the group aged <50 years. After adjusting for age, the PCT AUROC value was 0.77 for predicting pathogen-positive results of REBA Sepsis-ID. The optimal cutoff values of PCT concentrations for subsequent application of REBA Sepsis-ID were 0.12 ng/mL in all patients and 0.22 ng/mL in patients aged ≥50 years. Our observations showed that REBA Sepsis-ID using whole blood was advantageous for the early detection of sepsis-causing microorganisms, and the PCT concentration could be used to determine the necessity of using REBA Sepsis-ID in clinical settings. The application of REBA Sepsis-ID using whole blood, based on the PCT concentration, may contribute to a highly efficient detection of sepsis-causing microorganisms.

Highlights

  • Numerous studies have reported that the timely antimicrobial therapy can improve the outcomes in patients with sepsis

  • We investigated whether PCT and C-reactive protein (CRP) concentrations could assist in decision making regarding the use of reverse blot hybridization assay (REBA) Sepsis-ID in clinical settings

  • To evaluate the performance of REBA Sepsis-ID, we carried out blood culture (BC) and REBA Sepsis-ID simultaneously, using whole blood collected from these 440 patients

Read more

Summary

Introduction

Numerous studies have reported that the timely antimicrobial therapy can improve the outcomes in patients with sepsis. The Sepsis Surviving Campaign guidelines recommend the administration of effective intravenous antimicrobials within the first hour of the recognition of septic shock or severe sepsis without septic shock as the goal of therapy, with daily reassessment of the antimicrobial regimen for potential de-escalation [2]. Effective, this treatment can destroy the human body’s normal microbiota by indiscriminately attacking both virulent and avirulent or beneficial microorganisms [3]. Optimization of the laboratory workflow, technological innovations such as rapid AST platforms, and further laboratory automation are required for reducing the microbiological TAT [5]

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call